FTSE MIB
33.555,01 -152,20 (-0,45%) Dow Jones
39.059,23 -52,93 (-0,14%) Nasdaq
17.736,96 +19,31 (+0,11%) Nikkei 225
39.667,07 +493,92 (+1,26%) Petrolio
80,83 0,00 (0,00%) Bitcoin EUR
57.501,26 -354,45 (-0,61%)
Pulmonx Corporation (LUNG)
- GlobeNewswire
Pulmonx Announces CFO Transition and Record Preliminary Third Quarter 2023 Revenue
Derrick Sung steps down from his position as Chief Financial Officer to pursue another opportunity; John McKune appointed Interim Chief Financial OfficerPreliminary, unaudited third quarter 2023 revenue expected to be approximately $17.6 millionManagement to host conference call on October 30, 2023 to discuss third quarter 2023 financial results REDWOOD CITY, Calif., Oct. 10, 2023 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally in
- GlobeNewswire
Pulmonx to Participate at Upcoming Investor Conferences
REDWOOD CITY, Calif., Aug. 30, 2023 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a global leader in minimally invasive treatments for severe lung disease, today announced the company will be participating in two upcoming investor conferences. Pulmonx management is scheduled to participate in a fireside chat at the 2023 Wells Fargo Healthcare Conference in Boston on Wednesday, September 6, 2023, at 11:15am PT / 2:15pm ET. Interested parties may access a live and archived web
- GlobeNewswire
Pulmonx Reports Second Quarter 2023 Financial Results
REDWOOD CITY, Calif., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for lung disease, today reported financial results for the second quarter of 2023 ended June 30, 2023. Recent Highlights Achieved record worldwide revenue of $17.2 million in the second quarter of 2023, a 23% increase over the same period last yearDelivered a new high of $11.0 million in U.S. revenue in the second quarter of 202
